FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2063640902> ?p ?o ?g. }

• W2063640902 endingPage "214" @default.
• W2063640902 startingPage "203" @default.
• W2063640902 abstract "BACKGROUND. MPS160 (GRAMLGTHTMEVTV) is a glycoprotein 100-derived melanoma peptide that contains overlapping human leukemic antigen A2-, DR53-, and DQw6-restricted T-cell epitopes. In preclinical testing, MPS160 demonstrated superior immunization and antitumor activity. In this report, the authors present the results from a clinical trial that evaluated the safety and immunologic efficacy of the MPS160 vaccine in patients with metastatic melanoma. METHODS. Patients with stage IV melanoma were randomized to 1 of 3 treatment arms: 1) MPS160 in incomplete Freund adjuvant (Montanide ISA-51); 2) MPS160 in Montanide ISA-51 with 75 μg of granulocyte-macrophage–stimulating factor (GM-CSF); or 3) MPS160 in Montanide ISA-51 with 100 μg of GM-CSF. Vaccines were administered every 3 weeks until patients developed disease progression or severe toxicity. Patients were aged ≥18 years with metastatic melanoma and a good performance status. Exclusion criteria included pregnancy/nursing, brain metastases, and ongoing chemotherapy. Immunologic efficacy was ascertained by using tetramer and functional analysis of peripheral blood lymphocytes. RESULTS. None of the 28 patients exhibited objective tumor responses or severe toxicities. Four patients remained progression free for ≥100 days. Immunologic analysis was available for 21 patients. Laboratory data demonstrated 1) increased frequency of vaccine-specific, nonfunctional cytotoxic T lymphocytes in 10 patients; 2) no differences in immunization efficacy among the treatment arms; and 3) evidence of systemic cytokine/immune dysfunction. CONCLUSIONS. Clinically, the MPS160 vaccine was ineffective. Phenotypic (tetramer) evidence of immunization was ineffective functionally and most likely was caused by global immune dysfunction, as illustrated by abnormal cytokine profiles in peripheral blood. In this report, the authors discuss possible implications of the current results on future cancer vaccine studies. Cancer 2007. © 2007 American Cancer Society." @default.
• W2063640902 created "2016-06-24" @default.
• W2063640902 creator A5032554768 @default.
• W2063640902 date "2007-01-01" @default.
• W2063640902 modified "2023-09-27" @default.
• W2063640902 title "Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma" @default.
• W2063640902 cites W1503844819 @default.
• W2063640902 cites W1517416547 @default.
• W2063640902 cites W1585754595 @default.
• W2063640902 cites W1950572133 @default.
• W2063640902 cites W1960585934 @default.
• W2063640902 cites W1982889687 @default.
• W2063640902 cites W1982951034 @default.
• W2063640902 cites W1985770829 @default.
• W2063640902 cites W2000786003 @default.
• W2063640902 cites W2007752528 @default.
• W2063640902 cites W2015620306 @default.
• W2063640902 cites W2022622965 @default.
• W2063640902 cites W2031322186 @default.
• W2063640902 cites W2034936705 @default.
• W2063640902 cites W2035591127 @default.
• W2063640902 cites W2050302729 @default.
• W2063640902 cites W2053308866 @default.
• W2063640902 cites W2061203368 @default.
• W2063640902 cites W2063461000 @default.
• W2063640902 cites W2068971398 @default.
• W2063640902 cites W2069683093 @default.
• W2063640902 cites W2070703301 @default.
• W2063640902 cites W2088571368 @default.
• W2063640902 cites W2098020683 @default.
• W2063640902 cites W2103018035 @default.
• W2063640902 cites W2114239197 @default.
• W2063640902 cites W2148523692 @default.
• W2063640902 cites W2163184777 @default.
• W2063640902 cites W2164584613 @default.
• W2063640902 cites W36309855 @default.
• W2063640902 cites W4230861071 @default.
• W2063640902 doi "https://doi.org/10.1002/cncr.22744" @default.
• W2063640902 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17541944" @default.
• W2063640902 hasPublicationYear "2007" @default.
• W2063640902 type Work @default.
• W2063640902 sameAs 2063640902 @default.
• W2063640902 citedByCount "35" @default.
• W2063640902 countsByYear W20636409022012 @default.
• W2063640902 countsByYear W20636409022013 @default.
• W2063640902 countsByYear W20636409022014 @default.
• W2063640902 countsByYear W20636409022015 @default.
• W2063640902 countsByYear W20636409022016 @default.
• W2063640902 countsByYear W20636409022019 @default.
• W2063640902 countsByYear W20636409022021 @default.
• W2063640902 countsByYear W20636409022023 @default.
• W2063640902 crossrefType "journal-article" @default.
• W2063640902 hasAuthorship W2063640902A5032554768 @default.
• W2063640902 hasBestOaLocation W20636409021 @default.
• W2063640902 hasConcept C126322002 @default.
• W2063640902 hasConcept C147483822 @default.
• W2063640902 hasConcept C203014093 @default.
• W2063640902 hasConcept C2777658100 @default.
• W2063640902 hasConcept C2777701055 @default.
• W2063640902 hasConcept C2777863537 @default.
• W2063640902 hasConcept C502942594 @default.
• W2063640902 hasConcept C71924100 @default.
• W2063640902 hasConcept C8891405 @default.
• W2063640902 hasConceptScore W2063640902C126322002 @default.
• W2063640902 hasConceptScore W2063640902C147483822 @default.
• W2063640902 hasConceptScore W2063640902C203014093 @default.
• W2063640902 hasConceptScore W2063640902C2777658100 @default.
• W2063640902 hasConceptScore W2063640902C2777701055 @default.
• W2063640902 hasConceptScore W2063640902C2777863537 @default.
• W2063640902 hasConceptScore W2063640902C502942594 @default.
• W2063640902 hasConceptScore W2063640902C71924100 @default.
• W2063640902 hasConceptScore W2063640902C8891405 @default.
• W2063640902 hasIssue "1" @default.
• W2063640902 hasLocation W20636409021 @default.
• W2063640902 hasLocation W20636409022 @default.
• W2063640902 hasOpenAccess W2063640902 @default.
• W2063640902 hasPrimaryLocation W20636409021 @default.
• W2063640902 hasRelatedWork W1481917790 @default.
• W2063640902 hasRelatedWork W1976102012 @default.
• W2063640902 hasRelatedWork W2034807705 @default.
• W2063640902 hasRelatedWork W2090324576 @default.
• W2063640902 hasRelatedWork W2093242067 @default.
• W2063640902 hasRelatedWork W2200295633 @default.
• W2063640902 hasRelatedWork W2220102944 @default.
• W2063640902 hasRelatedWork W2388431301 @default.
• W2063640902 hasRelatedWork W3109192410 @default.
• W2063640902 hasRelatedWork W276659083 @default.
• W2063640902 hasVolume "110" @default.
• W2063640902 isParatext "false" @default.
• W2063640902 isRetracted "false" @default.
• W2063640902 magId "2063640902" @default.
• W2063640902 workType "article" @default.